Hooke

EQS-News: Biotech Company Pleased With Results Of Early Testing Demonstrating Vaccine Potential For Multiple Sclerosis

Retrieved on: 
Monday, October 3, 2022
National Academy of Sciences, MRNA, Injection, CNS, Vaccine, Lists of diseases, AstraZeneca, National academy, NASDAQ, Incidence, Advertising, Johnson & Johnson, Amyotrophy, Science, MS, EAE, Technology, Research, Disease, Nature, Psychopharmacology, Hooke, Natalizumab, Psychiatry, Brain, National, KTTA, COVID-19, Epstein–Barr virus, Ketamine, Immune system, Laboratory, ALS, Therapy, Spinal cord, NYSE, Autoimmune disease, Plasma, Multiple sclerosis, Patient, Central nervous system, Paralysis, Crohn's disease, Infection, EBV, White matter, DNA, Amyotrophic lateral sclerosis, Encephalitis, Histology, JNJ, Monkeypox, Pharmaceutical industry

Pasithea is a biotechnology company focused on discovering, researching and developing new and effective treatments for psychiatric and neurological disorders.

Key Points: 
  • Pasithea is a biotechnology company focused on discovering, researching and developing new and effective treatments for psychiatric and neurological disorders.
  • Pasithea recently announced encouraging preclinical results that support the efficacy of a tolerizing DNA vaccine for multiple sclerosis (MS).
  • Based on its experiments conducted with Hooke Laboratories Inc., Pasithea reported that intramuscular injections of the candidate vaccine (PAS002) delayed the onset of paralysis and reduced peak disease severity.
  • Moderna Inc. (NASDAQ: MRNA), meanwhile, has started testing the vaccine mRNA-1189 in Phase I studies but does not indicate MS, though the company believes it could potentially assist in prevention.

Pasithea Therapeutics Initiates New Chemical Entity Drug Development Program in Multiple Sclerosis

Retrieved on: 
Thursday, February 3, 2022
KTTA, Lists of diseases, Forward-looking statement, Patient, Therapy, Immune system, Neurodegeneration, Ketamine, Central nervous system, SEC, Optic nerve, Brain, Biotechnology, Crohn's disease, EAE, Laboratory, Psychiatry, Pasithea (Charites), Research, MS, Natalizumab, Contract research organization, Program, Autoimmune disease, Psychopharmacology, Company, MIAMI, Hooke, GLOBE, National Academy of Sciences, Doctor of Philosophy, National academy, Science, Spinal cord, Multiple sclerosis, Nasdaq, Nerve, Pharmaceutical industry, Vaccine, MD

Prof. Steinman is a world recognized leading authority in MS, and his research led to the development of the drug Tysabri, which is approved to treat patients with MS and Crohn's disease.

Key Points: 
  • Prof. Steinman is a world recognized leading authority in MS, and his research led to the development of the drug Tysabri, which is approved to treat patients with MS and Crohn's disease.
  • Our decision to initiate a program in MS is a strong strategic fit and a natural progression of our work and mission, stated Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea Therapeutics.
  • Multiple sclerosis is a chronic and potentially disabling autoimmune disease, and the most common neurodegenerative disease of the central nervous system in young adults.
  • Pasithea Therapeutics Corporation is a U.S. biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders.